XBIOW

Xenetic Biosciences, Inc. [XBIOW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XBIOW Stock Summary

In the News

XBIOW Financial details

Company Rating
-
Market Cap
7.22M
Income
-4.08M
Revenue
2.54M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-1.3
Forward P/E
-
PEG
0.32
P/S
2.39
P/B
0.51
P/C
-
P/FCF
-1.38
Quick Ratio
9.15
Current Ratio
10.54
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.67
EPS next Y
-
EPS next Q
-
EPS this Y
-39.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-45.41%
Revenue last 5Y
171.98%
Revenue Q/Q
9.95%
EPS Q/Q
10.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-36%
ROE
-35%
ROC
-0.44%
Gross Margin
100%
Oper. Margin
-205%
Profit Margin
-183%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.7-23.16
52W High
-
52W Low
-
RSI
-
Rel Volume
0.01
Avg Volume
375
Volume
2
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.668
-
-
Volatility
0%, 0%
Prev Close
0%
Price
17.54
Change
0%

Something similar

Top by Market Cap
EMBASSY.NS
AVGO
VTSAX
FXAIX
TL0.DE
Same Sector
CYTK
7775.T
4581.T
ERIS.NS
SPHRY
Check Those
CHB.TO
PA9.DE
0QYH.L
SOLG.TO
600667.SS
Similar Market Cap
ALAGR.PA
FDIU.L
WDLF
MOJO
RITA

Company Profile

Healthcare Biotechnology
  • Volume Average 375
  • Market Capitalization 7.22M
  • Employee 4
  • CEO Mr. Jeffrey F. Eisenberg Esq.
  • Headquarters US
  • IPO Date 2019-07-23

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.